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Abstract
Background. Antimicrobial resistance is an emerging global health issue. Data on the epidemiology of multidrug-resistant
organisms are scarce for Africa, especially in HIV-infected individuals who often have frequent contact with healthcare. We
investigated the prevalence of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) carriage in stool
among HIV-infected children attending an HIV outpatient department in Harare, Zimbabwe.
Methods. We recruited children who were stable on antiretroviral therapy (ART) attending a HIV clinic from August 2014 to
June 2015. Information was collected on antibiotic use and hospitalization. Stool was tested for ESBL-E through combination
disc diffusion. API20E identification and antimicrobial susceptibility was performed on the positive samples followed by
whole genome sequencing.
Results. Stool was collected from 175/202 (86.6%) children. Median age was 11 [inter-quartile range (IQR) 9–12] years.
Median time on ART was 4.6 years (IQR 2.4–6.4). ESBL-Es were found in 24/175 samples (13.7%); 50% of all ESBL-Es were
resistant to amoxicillin-clavulanate, 100% to co-trimoxazole, 45.8% to chloramphenicol, 91.6% to ceftriaxone, 20.8% to
gentamicin and 62.5% to ciprofloxacin. ESBL-Es variously encoded CTX-M, OXA, TEM and SHV enzymes. The odds of ESBL-E
carriage were 8.5 times (95%CI 2.2–32.3) higher in those on ART for less than one year (versus longer) and 8.5 times
(95%CI 1.1–32.3) higher in those recently hospitalized for a chest infection.
Conclusion. We found a 13.7% prevalence of ESBL-E carriage in a population where ESBL-E carriage has not been
described previously. Antimicrobial resistance (AMR) in Africa merits further study, particularly given the high HIV
prevalence and limited diagnostic and therapeutic options available.
INTRODUCTION
The widespread use of antibiotics worldwide has resulted in
the emergence of a global problem of antimicrobial resis-
tance (AMR). Over the past decade, there has been an
increasing prevalence of carriage of and infection with
multidrug-resistant organisms (MDROs) such as extended-
spectrum beta-lactamase-producing Enterobacteriaceae
(ESBL-E) and carbapenemase-producing Enterobacteria-
ceae (CPE) [1]. ESBL and carbapenemase enzymes are most
commonly located on plasmids and transposons, which can
facilitate transmission of resistance within and between
species, and carriage therefore presents an infection control
risk particularly within hospitals. Mobile genetic elements
(MGEs) are a type of resistance encoded by a plasmid which
can transfer antibiotic resistance to different bacteria and
are increasingly recognized as an additional infection con-
trol risk within healthcare settings. In the community, a
French study reported a 10-fold increase in ESBL-E stool
carriage from 0.6% in 2006 to 6% in 2011 among healthy
volunteers attending a free five-yearly medical check-up
programme [2]. The prevalence of ESBL-E rectal carriage
in a more recent study of French children on routine
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check-ups at home by community paediatricians doubled
between 2010 and 2015, from 4.8 to 10.2% [3].
The emerging global threat of antimicrobial resistance
(AMR) is particularly concerning for developing countries,
as infections with ESBL-E and CPE are difficult to treat due
to limited antibiotic treatment options that are not readily
available in most resource-limited settings.
While the epidemiology, phenotypic and genotypic charac-
teristics of MDROs are well described in Europe, North
America and Asia [1], such data are scarce for Sub-Saharan
Africa [4, 5]. African studies reporting on the prevalence of
ESBL-E and CPE are mainly in the context of infection
rather than carriage [5–8]. A study from the Central African
Republic estimated the prevalence of ESBL-E in faeces of
healthy children to be 59% (79/134). CTX-M-15 was found
in 81/83 (97.6%) strains isolated and 39/51 (76%) of the
isolated Escherichia coli isolated pertained to the pandemic
ST131 group [9].
Sub-Saharan Africa is the epicentre of the HIV epidemic, host-
ing an estimated 70% (approximately 25million) of the
world’s HIV-infected population in 2014 [10]. Individuals liv-
ing with HIV infection are at particular risk of acquiring
MDROs due to the use of antibiotic prophylaxis and a high
incidence of bacterial infections necessitating frequent antibi-
otic use. However, there is a dearth of studies investigating
AMR carriage in the context of HIV infection. A study of 203
HIV-positive children recruited from outpatient clinics in
Cape Town documented, in 2008, a 14.8% nasopharyngeal
carriage rate of Enterobacteriaceae, 50% of which were ESBL-
Es [11]. It is not yet known how carriage of these resistant bac-
teria from such a young age might affect the epidemiology of
MDROs in this population as it grows older. Given the eco-
nomic, environmental and healthcare-setting diversities
between countries in Sub-Saharan Africa, it is important to
obtain local epidemiological data on MDROs to develop strat-
egies to address this growing problem.
The aim of our study was to determine the prevalence of
ESBL-E and CPE carriage in stool among HIV-infected chil-
dren accessing outpatient HIV care in Harare, Zimbabwe.
METHODS
Study population
This study was conducted at the paediatric HIV care clinic
at Harare Central Hospital, the largest public sector hospital
in Harare, Zimbabwe. The clinic provides HIV care to over
3000 children. This study was nested in a larger study inves-
tigating the epidemiology of HIV-associated chronic lung
disease (INHALE study). Perinatally HIV-infected children
aged between 6 to 16 years who had been taking antiretrovi-
ral therapy (ART) for at least 6 months and were not acutely
unwell were recruited consecutively over a 10-month
period, with guardian consent and participant assent. Ethi-
cal approval for the study and shipment of specimens was
granted by the Medical Research Council of Zimbabwe and
the Research Council of Zimbabwe.
Study procedures
A questionnaire recording socio-demographic details and
clinical history, including duration of ART use and previ-
ous hospitalization, was administered on site to all partic-
ipants/guardians. CD4 count was measured using the
Alere PIMA analyser (Alere Technologies, Jena, Germany)
and HIV viral load was measured using the COBAS
Ampliprep/Taqman 48 version 2.0 (Roche Molecular Sys-
tems, Branchburg, USA). Participants were asked to pro-
vide a fresh stool sample on site or at home on the
morning of the second study visit (INHALE study), using
a stool collection kit and transported on ice if the partici-
pant had a freezer.
Laboratory procedures
Freshly collected stool samples were inoculated onto cyste-
ine lactose electrolyte-deficient (CLED) medium with the
addition of a cefpodoxime disc (as indicator cephalosporin)
for ESBL-E screening, and an ertapenem disc for CPE
screening. Each colonial morphotype of oxidase-negative
Gram-negative isolates that grew within a diameter zone of
inhibition of 20mm around the cefpodoxime disc or
28mm around the ertapenem disc was subcultured for
ESBL-E and CPE screening, respectively, and based on
British Society for Antimicrobial Chemotherapy (BSAC)
breakpoints [12]. ESBL-E detection was performed using
combination disc diffusion testing following guidelines
issued by Public Health England (PHE) [13]. The following
discs were used and comparisons were made: cefpodoxime
30 µg±clavulanic acid and cefepime 30 µg±clavulanic acid
(looking for a change in diameter zone 5mm for ESBL
confirmation). Organisms showing resistance to cefpodox-
ime without clavulanic acid synergy and susceptibility to
cefepime were assumed to carry AmpC enzymes (or other
inhibitor-stable beta-lactamases) and, given the identity of
the organisms (E. coli), any AmpC genes would be likely to
be plasmid-associated.
Preliminary identification of these resistant organisms was
performed using API20E (BioMerieux, Lyon, France) and
was subsequently confirmed using MALDI-TOF (MALDI
Biotyper, Bruker, Bremen, Germany). Antimicrobial suscep-
tibility testing (AST) was performed by disc diffusion testing
following EUCAST methodology [14]. Isolates were tested
against a range of antibiotics including those most com-
monly found in the Zimbabwean public health sector
(amoxicillin-clavulanate, co-trimoxazole, chloramphenicol,
ceftriaxone, trimethoprim, gentamicin and ciprofloxacin),
those restricted to the private sector (piperacillin-tazobac-
tam and meropenem) and those not known to be used in
Zimbabwe (amikacin and temocillin). Disc diffusion as a
method for ESBL-E screening and detection is recom-
mended by the following agencies: Centres for Disease
Control and Prevention (CDC), Clinical and Laboratory
Standards Institute (CLSI) [15], as well as PHE and the
Advisory Committee on Antimicrobial Resistance and
Healthcare Associated Infection (ARHAI) [13].
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DNA extraction and sequencing
DNA was extracted from RNase-treated lysates using a Qia-
symphony DSP DNA midi kit (Qiagen, Hilden, Germany).
DNA libraries were prepared using the NexteraXT sample
preparation method and sequenced with a standard 2101
base protocol on a HiSeq 2500 Instrument (Illumina, San
Diego, CA, USA). Sequence data from the sequencing runs
were deplexed and trimmed, and the presence of antimicro-
bial resistance genes was determined with ‘Genefinder’ as
described previously [16]. Genome assembly was performed
using VelvetOptimiser with k-mer values from 47 to 71.
BLAST searching against multi-locus sequence type (MLST)
databases was used to identify the nearest match for each
allele, followed by assignation of allelic profiles.
Data analysis
Data were entered using Cardiff TELEFORM Intelligent
Character Optical Mark Recognition Software (version
10.7) and analysed using STATA Version 13.1 (StataCorp,
Texas, USA). Descriptive statistics were performed on the
demographic and baseline characteristics of the participants.
For continuous variables, non-parametric medians and
inter-quartile ranges (IQRs) were calculated and for cate-
gorical variables, frequencies and percentages were deter-
mined. A 2 test or Fisher’s exact (or non-parametric
Mann–Whitney) test and univariate logistic regression were
used to assess the association between the variables of inter-
est and the occurrence of ESBL-E. A two-tailed P-value
of <0.05 was considered to represent a statistically signifi-
cant association. All the variables were considered regard-
less of their initial P-value into a multivariate logistic
regression to assess the adjusted net effect of the indepen-
dent variables.
RESULTS
A total of 202 eligible HIV-infected participants were
recruited between August 2014 and June 2015, of whom
175/202 (86.6 %) were able to provide a stool sample and
were included in this study. The median age was 11 (IQR 9–
12) years and 48% were female. The median time on ART
was 4.6 years (IQR 2.4–6.4) (Table 1) and 96% of partici-
pants were taking long-term prophylactic co-trimoxazole.
The median CD4 count was 710 (IQR 468–952) cells µl 1,
and 67.0% of the participants had a viral load
of <50 copiesml 1. Only 2% of the participants had been
admitted to the hospital for a chest infection/pneumonia in
the previous 12 months.
Laboratory analysis of the stool samples showed that 28/175
(16.0%) were positive for possible ESBL-Es on initial
screening. On confirmatory testing, 24 samples did contain
an ESBL-E giving an estimated ESBL-E prevalence of 13.7%
(95% CI 8.9–19.7) in this population. Of these, 23/24
(95.8%) were identified as E. coli and 1/24 (4.2%) as
K. pneumoniae. The other four resistant isolates included
three isolates identified as E. coli (not ESBL-producing) and
one isolate identified as Acinetobacter baumannii, which
was not further investigated. MALDI-TOF testing con-
firmed the identification of all organisms (data not shown).
No CPE were detected.
Bivariate analysis to assess the factors associated with ESBL-
E carriage found no demographic association with ESBL-E
carriage. Independent association, however, was found
between ESBL-E carriage and duration on ART (P=0.001)
whereby participants on ART for less than 1 year had 7.7
times (95%CI : 2.03–29.0) the odds of carrying an ESBL-E
(Table 2). Similarly, participants admitted to hospital for a
chest infection in the previous 12 months had 6.8 times the
odds of carrying ESBL-Es (95%CI : 0.9–50.6; P=0.033).
These factors remained significant when considered in the
final multivariate model when participants had eight times
the odds of carrying ESBL-Es. Demographic and other clini-
cal factors were included in the multivariate model despite
P-values>0.2, and no significant association was observed
even in the adjusted model.
Results from AST on the ESBL-producers included 100%
resistance to co-trimoxazole, 91.6% to ceftriaxone, 62.5% to
ciprofloxacin, 45.8% to chloramphenicol and 20.8% to gen-
tamicin (see Table 3). All organisms were sensitive to ami-
kacin and meropenem.
The 27 isolates (i.e. 23 ESBL-positive E. coli, one ESBL-
positive K. pneumoniae and three E. coli with AmpC
enzymes) were genetically diverse, represented by 16 differ-
ent MLSTs (15 STs in E. coli, 1 K. pneumoniae). Molecular
characteristics of the isolates relevant to this paper are dis-
played in Table 3. The detail of these CTX-M genes is part
of an analysis of flows of resistance genes and bacterial
groups, which is beyond the scope of this work. The flow of
CTX-M genes, bacterial serogroups, clades and sub-clades
will be described in a subsequent phylogeography-focused
analysis. The E. coli were predominated by nine ST131 iso-
lates with the remainder comprised of two isolates each of
STs 48, 656 and 1589, and 11 singletons. The ESBLs were
predominated by CTX-M enzymes, comprising mainly
group-9 CTX-Ms (six CTX-M-27 and four CTX-M-14) fol-
lowed by seven CTX-M-15 and four CTX-M-3, both in
group 1 (Table 3). Three isolates had acquired AmpC-type
b-lactamases (two DHA-1 and one CMY-2). Group 1 and
group 9 CTX-M ESBLs were disseminated across multiple
STs and, in the case of group 1, found even in a different
species (K. pneumoniae).
A duration of ART treatment of less than 1 year was associated
with a significantly higher ESBL-E carriage prevalence (20.8%
versus 3.3%, P=0.001), as was having been admitted to hospi-
tal for a chest infection in the past 12 months (8.3% versus
1.3%, P=0.033; Table 1). There was no association between
ESBL-E carriage and sex, age, CD4 count or viral load.
DISCUSSION
The key finding of this study was an ESBL-E carriage preva-
lence of 13.7% among children attending routine outpatient
HIV care. This is lower than the recently (2016) reported
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outpatient setting carriage prevalence estimate of 59% (79/
134) in rectal swabs from healthy young children in the
Central African Republic and higher than the 7.4% in naso-
pharygeal swabs from HIV-infected children in Cape Town.
Among the ESBL-E isolates, there was a high level of resis-
tance to co-trimoxazole, ciprofloxacin, chloramphenicol
and gentamicin. Participants enrolled in the current study
were often repeatedly exposed to inpatient and outpatient
environments and to have received multiple courses of anti-
biotics throughout their short lives due to their chronic
immunodeficient state. Carriage was associated with having
started ART recently and having been hospitalized with a
chest infection in the previous 12 months. Unfortunately,
reliable information on previous antibiotic usage was not
available and parents were often unsure of the exact treat-
ment their child had received.
Two recent reviews on MDRO prevalence in Africa reported
ESBL-E prevalence rates ranging from 1.3–22.8% in urine
and 0.7–75.8% in blood [5, 17]. Unfortunately the analysis
was not stratified by region. Another study from Malawi
reported a very low prevalence of 0.7 % ESBL-Es in blood-
stream infections in 2005 in adult and paediatric medical
wards in a large government tertiary hospital in Blantyre
[18]. This was at a time when ceftriaxone, the only third
generation cephalosporin available in many African coun-
tries, was not yet widely available in Malawi. ESBL-E preva-
lence is likely to have increased throughout Africa in line
with the reported global ESBL-E increase worldwide [2, 5, 7].
Being admitted to hospital within the previous 12 months
for a chest infection was associated with ESBL-E carriage
(P=0.033). This points to the possibility of having acquired
the ESBL-E while in hospital. The other potential significant
risk factor was having been on ART for less than 1 year
(P=0.002). These children are likely to have been immuno-
suppressed more recently and to have received antibiotics
and/or to have recent contact with healthcare services, com-
pared to children well established on ART for years.
The ESBL-Es identified in this study were resistant to
multiple classes of antibiotics. All isolates were resistant to
co-trimoxazole with less resistance to ciprofloxacin (60%),
chloramphenicol (45%), gentamicin (20%) and temocillin
(12%), and none to amikacin. The level of resistance reflects
the usage of these antibiotics in the public sector in
Zimbabwe. All HIV-infected individuals receive long-term
co-trimoxazole for prophylaxis, and WHO guidelines rec-
ommend continuation of co-trimoxazole in children even
following immune reconstitution with ART [19]. Ciproflox-
acin is frequently used in the community setting and is the
Table 1. Demographic and clinical characteristics
All (n=175) ESBL-E negative (n=151) ESBL-E positive (n=24) P-value
Demographics
Gender
Male 91 (52.0%) 80 (53.0%) 11 (45.8%)
Female 84 (48.0%) 71 (47.0%) 13 (54.2%) 0.515
Age (years)
6–11 113 (64.6%) 99 (65.6%) 14 (58.3%)
12–16 62 (35.4%) 52 (34.4%) 10 (41.7%) 0.492
Median age (IQR) years 11 (9–12) 11 (8–12) 11 (9–13) 0.291
Current CD4 count (cells µl 1)
<350 19 (10.9%) 15 (9.9%) 4 (16.7%) 0.325
350 156 (89.1%) 136 (90.1%) 20 (83.3%)
Median CD4 count (IQR) 710 (468–952) 710 (472–952) 699 (409–944) 0.548
Current viral load (copies ml 1)
50 117 (66.8%) 101 (66.9%) 16 (66.7%)
>50 57 (32.6%) 49 (32.5%) 8 (33.3%) 0.948
Missing 1 (0.6%) 1 (0.7%) 0 (0.0%)
Duration on ART (months)
12 months 10 (5.73%) 5 (3.3%) 5 (20.8%) 0.001
>12 months 165 (94.3%) 146 (96.7%) 19 (79.2%)
Median duration on ART (IQR) years 4.6 (2.4–6.4) 4.8 (2.7–6.4) 3.5 (1.5–6.6) 0.145
Clinical characteristics
Admitted to the hospital in last 12 months
No 166 (94.9%) 144 (95.4%) 22 (91.7%)
Yes 9 (5.1%) 7 (4.6%) 2 (8.3%) 0.446
Admitted to the hospital for a chest infection/pneumonia in last 12 months
No 171 (97.7%) 149 (98.7%) 22 (91.7%)
Yes 4 (2.3%) 2 (1.3%) 2 (8.3%) 0.033
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antibiotic of choice in children presenting with diarrhoeal
illnesses and fever in primary care [20]. Ceftriaxone and
chloramphenicol are used interchangeably for meningitis
treatment depending on availability in the public sector.
While ceftriaxone is the first-line antibiotic for most infec-
tions requiring antibiotic treatment in a hospital setting,
meropenem is not available in the public sector in
Zimbabwe, which may account for the lack of carbapene-
mase producers.
Our observation of multiple cases affected by ST131 E. coli
aligns with the predominance of this ST in many other parts
of the world [21] and its enhanced virulence, and consti-
tutes the first report, to our knowledge of this lineage in
Zimbabwe. Moreover, all of the ESBL E. coli we observed,
including the ST131 isolates, encoded ESBLs alongside mul-
tiple other resistances (co-trimoxazole, aminoglycosides and
fluoroquinolones). Concurrent antimicrobial resistance lim-
its treatment options and is known to be typically encoded
on plasmids and transposons that are capable of intra- and
inter-species spread. If carriage in these children were to
result in urinary or bloodstream infections, gentamicin
would be the only available antibiotic with a reasonable
chance of treatment success.
The study was conducted in the public sector among
asymptomatic and previously unstudied HIV-infected
children and adolescents. Multiple standardized and well-
established methods were used to identify ESBL-E pheno-
typically and genotypically. However, the sample size was
small resulting in reduced power to identify risk factors. A
limitation of this study was that no comparison was made
with HIV-negative children to ascertain whether ESBL-E
carriage was associated with HIV status. Thus whether the
prevalence of 13.7% is specific to this patient population or
due to a high carriage rate in the community is unknown
and requires further investigation. Variables such as self-
reported hospitalization are subject to recall bias, although
we attempted to confirm contact with health services from
patient-held clinical records. Participants may have been
hospitalized for other infections, but as this study was
embedded in a study investigating chronic lung disease,
only hospitalisations for lung-related infections were
recorded. However, respiratory tract infection is the most
Table 2. Univariate and multivariate analysis of factors associated with ESBL-E carriage
Univariate OR
(95%CI)
P-
value
Adjusted
multivariate OR (95%CI)
Final adjusted
multivariate OR (95%CI)
Demographics
Gender
Male 1 1 –
Female 1.33 (0.56–3.16) 0.516 1.31 (0.51–3.36)
Age (years)
6–11 1 1
12–16 1.36 (0.57–3.27) 0.493 1.15 (0.44–2.96) –
Median age (IQR) years 0.291
Current CD4 count (cells µl 1)
<350 1.81 (0.55–6.01) 0.330 1.08 (0.21–5.49) –
350 1
Median CD4 count (IQR) 0.548
Current viral load (copies ml 1)
50 1 1
>50 1.03 (0.41–2.57) 0.948 0.93 (0.29–3.00) –
Missing –
Duration on ART (years)
1 7.68 (2.03–29.0) 0.003 8.19 (2.06–32.48) 8.47 (2.22–2.27)
>1 1 1 1
Median duration on ART (IQR) years 0.145
Clinical characteristics
Admitted to the hospital in last 12 months
No 1
Yes 1.87 (0.36–95.6) 0.453 – –
Admitted to the hospital for a chest infection/pneumonia in
last 12 months
No 1 1
Yes 6.77 (0.907–
50.587)
0.062 8.12 (0.98–67.17) 8.47 (1.12–64.07)
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common infection among HIV-infected children, including
among those who are immunocompetent.
The ESBL-E prevalence identified in this study carries sev-
eral important implications. First, the carriers themselves
are at risk of becoming infected. Gram-negative sepsis due
to ESBL-Es remains largely untreated in this setting and is
associated with very high mortality. Second, these children
are in recurrent contact with health services and, as such,
the ESBL-E carriage has implications for infection control.
Finally, this study is a reminder of how the use of ceftriax-
one, a broad-spectrum third-generation cephalosporin
widely used as a first-line antibiotic for sepsis and meningi-
tis throughout Sub-Saharan Africa [22], might favour the
spread of ESBL-Es. Limited diagnostic capacity for identify-
ing the source of sepsis and the causative organism and its
susceptibilities contribute to the widespread use of broad-
spectrum cephalosporins in this region. In order to assess
the prevalence of MDROs in Sub-Saharan Africa, it is
important to address the severe limitations in microbiolog-
ical diagnostic facilities for their detection and to enable
targeted antimicrobial therapy and minimize the overuse of
broad-spectrum empiric antibiotics.
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19 E. coli 1589 ESBL CTX-M (gp 1) S S S S R R R R
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21 E. coli 3036 AmpC§ DHA-1 S S S S S R R S
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ESBL CTX-M (gp 1), OXA-1, TEM-1 R R S R R R R R
23 E. coli ST202
(SLV)
ESBL CTX-M (gp 9) S S S S S R R R
24 E. coli ST2601
(SLV)
ESBL CTX-M (gp 1) S S S S S R R R
25 E. coli ST2753
(SLV)
ESBL CTX-M (gp 9), TEM-1 S S S S S R R R
26 E. coli ST224 ESBL CTX-M (gp 1) S S S S R R R R
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